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1. Introduction to pharmacovigilance
Worldwide, pharmacovigilance is one of the most important scientific  
disciplines within public health [1]. According to the World Health Organization 
(WHO), pharmacovigilance is described as “the science and activities relating to 
the detection, assessment, understanding and prevention of adverse effects or 
any other drug-related problem” [2]. The implementation of pharmacovigilance 
activities was essential to globally promote and protect public health, particularly 
by reducing the significant burden of morbidity, mortality and associated increased 
healthcare costs, triggered by the occurrence of adverse reactions to medicines [3]. 
The Memo/08/782, released in 2008 by the European Commission, highlights the 
importance of pharmacovigilance, namely for saving lives, by revealing estimates of 
about 197 thousand deaths per year and total costs to society of 79 billion euros in 
the European Union (EU), due to adverse reactions [4].
The fundamental goals of pharmacovigilance are [5–7]:
• To early identify drug-related problems, such as the occurrence of adverse 
reactions and other interactions previously unrecognized, reporting the 
resulting outcomes in a timely manner;
• To detect changes in the incidence of known adverse reactions;
• To carefully monitor and assess the benefit, harm, side-effects, efficacy and 
risks, together with the risk–benefit profile, of commercialized medicines, 
aiming to reduce their risks and increase their benefits during the drug’s 
lifecycle;
• To boost the prudent, rational and more effective (including cost-effective) 
use of several drugs;
• To strengthen patient’s care and safety, and consequently safeguard public 
health, concerning the use of medicines, including paramedical interventions;
• To promote education, knowledge, accurate information and clinical training 
in the field of drug safety and ensure its effective communication and acces-
sibility to the public.
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In sum, the golden objective of pharmacovigilance process is to enhance patient’s 
safety and quality of life, and strictly preserve public health by identifying, pre-
venting or decreasing the harmful effects and risks related to the use of health 
products in humans. Therefore, the science that assesses drug’s safety and efficacy 
profiles stands as highly important throughout the entire drug development life-
cycle, from preclinical development until post-market surveillance, as it promotes 
the continuous vigilance of the drug effects. It plays a crucial role within pharma-
ceuticals, not only for the prevention of drug-related risks in humans, as well as 
for the reduction of the financial expenses linked to the occurrence of unexpected 
adverse effects [5–8].
2. Pharmacovigilance history
Pharmacovigilance has a long history. Although the first findings were dated 
from 172 years ago, when a patient died after being anesthetized with chloroform, 
followed by 107 deaths in the United States of America in 1937, due to the high toxic-
ity caused by diethyleneglycol, a sulfanilamide elixir-containing solvent, its official 
inception to address drug safety problems was only heralded after the thalidomide 
tragedy, in 1961 [1, 8]. This drug was commonly used in Europe by pregnant women 
as a nonaddictive, nonbarbiturate sedative for nausea treatment, and resulted into 
a devasting 10 thousand birth abnormalities, namely phocomelia, and increased 
miscarriage rates [9]. At that time, Dr. McBride highlighted the link between the 
consumption of thalidomide in pregnancy and the prevalence of fetal congenital 
malformations, by writing a letter to The Lancet journal editor and reporting an 
increase of 20% in these cases. In response to the thalidomide disaster, it became 
evident the urgency in requiring the rigorous safety and efficacy testing of drugs 
before their market authorization, as well as a global awareness concerning the need 
for creating pharmacovigilance systems [8].
The pharmacovigilance system suffered many alterations since then and, due 
to a collaborative effort of many stakeholders, such as physicians, pharmacists, 
other healthcare professionals, patients, regulatory health authorities, academia 
and industry, in 1968 the WHO Pilot Research Programme for International Drug 
Monitoring was instituted. This program intended to establish an active, systematic, 
organized and regulated network at an international level, mainly for uncover-
ing formerly unknown or poorly recognized drug’s adverse effects, leading to the 
formal adoption of the pharmacovigilance term in the 1970s [7, 8]. In early 1980s, 
the Council for International Organizations of Medical Sciences (CIOMS) intro-
duced its programme on drug development and usage, together with WHO. In the 
1990s, a remarkable impact on international drug regulatory activity was observed, 
specifically after the implementation of various of the recommendations provided 
by CIOMS by the formerly International Conference on Harmonization (ICH), cur-
rently known as International Council for Harmonization [1, 7, 8]. The ICH helped 
to harmonize the regulatory infrastructures of the regulatory agencies and phar-
maceutical companies from Europe, Japan and the United States [1]. Thereafter, a 
positive development was observed in several countries, concerning the organiza-
tion and associated regulations of drug safety, ultimately resulting in the creation of 
the European Society of Pharmacovigilance (ESOP) in 1992, posteriorly renamed 
to International Society of Pharmacovigilance (ISoP). Finally, in 1995 the European 
Medicines Agency (EMA) was founded, followed by the Eudravigilance launch in 
2001 [7, 8].
Besides thalidomide disaster, another significant landmark in the history of 
pharmacovigilance was the market authorization of rofecoxib, a cyclooxigenase-2 
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inhibitor. In the end of 2000, the Vioxx Gastrointestinal Outcomes Research 
(VIGOR) study revealed an association between rofecoxib consumption and 
myocardial infections in patients with chronic pain [10–12]. By this time, this risk 
became a critical public health issue as rofecoxib was prescribed to tens of millions 
of people in more than 80 countries. This was one of the most highly publicized 
drug withdrawals ever reported and, together with other subsequent related 
episodes, raised some concerns regarding public trust on the role of pre- and post-
marketing surveillance [10–13]. Due to the public’s lack of confidence on pharma-
covigilance, more robust regulations had to be adopted [12, 14]. These include, 
for instance, the EU risk management plan, implemented in 2005, which became 
a mandatory document for marketing authorization applications to evaluate the 
information on drug toxicology, the request for a pharmacovigilance plan as well as 
for epidemiological information on the population receiving the drug therapy, and 
the submission of protocols to the regulatory authorities prior to the study start for 
a proper safety assessment [12]. Other important measures implemented were the 
education of physicians and medical students, active participation of other health 
professionals (pharmacists, nurses) in adverse drug reaction (ADR) reporting, 
feedback transmission and improvements on ADR reporting [14]. The introduction 
of all these approaches were essential to safeguard public health, with the particu-
larity of primarily assessing the effects on the population, especially on the patient, 
rather than over the drug under study [6, 12].
3. Pharmacovigilance systems
Given the high importance of pharmacovigilance, currently, countless countries 
around the world already have well-established, active and robust national pharma-
covigilance systems to safeguard patient’s wellbeing.
Pharmacovigilance activities of these systems can also involve the [1]:
1. establishment of the safety profile through data collection and management on 
the drug’s safety;
2. analysis of individual case reports to identify early signals of potential drug-
related security problems;
3. dynamic risk management to prevent the emergence of potential associated 
harmful risks following drug’s use; and.
4. information transmission to stakeholders and patients.
Therefore, it is not surprising that the WHO programme, responsible to aid 
in the design, development and assistance of the pharmacovigilance systems, has 
already 170 countries as partnership members [15].
3.1  WHO collaborating Center for International Drug Monitoring: the Uppsala 
monitoring Center
As previously referred, the WHO Programme for International Drug Monitoring 
started, in 1968, to systematically collect all available information on drug’s adverse 
effects, as a worldwide response to the thalidomide disaster. Ten years later, in 1978, 
with the intuit to support this programme, the Uppsala Monitoring Center (UMC) 
was set up. The UMC is an international, independent and non-profit center in 
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Uppsala, Sweden, devoted to investigating the harms and benefits of medicines, to 
ensure a safe and efficient consumption of these drugs by patients [5, 7].
The key mission of UCM, on behalf of the WHO, is to protect patients through 
an effective and global pharmacovigilance practice, namely the management of 
the international database of ADR reports received from each country national 
center, within the WHO’s global pharmacovigilance network [5, 7]. This distinc-
tive WHO data repository, known as VigiBase, is the world’s single largest database 
system of individual case safety reports (ICSR), which are solely submitted by 
members of the WHO programme [16]. The ICSR, also commonly recognized 
as “spontaneous” or voluntary ADR report, is a safety document that includes 
the information needed to support the reporting of adverse events, as well as of 
products-related problems and consumer complaints generated during the drug 
post-marketing phase. An ICSR can be filled either in paper or electronically and, 
to be considered as valid, has to include at least the following four elements: an 
identifiable patient, one identifiable reporter, one suspected medicinal product 
and one suspected adverse event [17, 18].
In sum, firstly the national pharmacovigilance system of each country receives 
the spontaneous ADR reports from health professionals, consumers and pharma-
ceutical companies. Afterwards, the ICSR are locally validated and evaluated, and 
a regulatory action can be potentially initiated, if needed. Finally, all the member 
countries are committed to disclose the on-time reports comprising complete post-
marketing data into VigiBase, therefore enabling the uncovering of ADR-associated 
signs between different countries.
Until May 2019, VigiBase has held over 20 million of ICSR associated with medi-
cines [16]. VigiBase collects the reports sent by the member countries of the WHO 
program, including 140 full member countries and 30 associate members [19]. The 
majority of the national joining centers have a straightforward electronic access to 
these standardized and structured reports, which contain a specific hierarchical 
code for the particular ADR registered, aiming to help in the fast identification of 
signals by any country member [5, 7]. The terminologies established for coding 
adverse reaction terms within the WHO programme, such as the WHO – Adverse 
Reaction Terminology (WHO-ART), afterwards replaced by the Medical Dictionary 
for Regulatory Activities (MedDRA), have been broadly embraced by national 
centers, manufacturers and medicinal product regulators [5, 7].
Spontaneous reporting systems are indispensable to post-marketing surveil-
lance, and have shown to be effective in detecting various types of ADR, especially 
rare ones. Moreover, the ADR report method also evaluates the need to pursuit 
further investigations to check if exists an association with the medicine and can 
hence trigger alarm signals [20]. However, the search for complements to the exist-
ing pharmacovigilance systems has shown to be extremely important, mainly due to 
the significant delays encountered on the detection of more common types of ADR, 
in addition to the persisting high amount of unreported ADR [20].
3.2 European Medicines Agency
Globally, it is possible to find a selection of regulatory authorities whose main 
function is to regulate and support pharmacovigilance. For instance, while in the 
United States, the responsible structure is the Food and Drug Administration 
(FDA), in the EU is the EMA [21].
Briefly, EMA’s gold mission relies on the promotion of scientific merit pertaining 
to medicine’s evaluation and oversight, for the benefit of public and animal health 
in the EU. In compliance with the EU legislation requirements, EMA’s main respon-
sibilities are related to the:
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1. supply and communication of independent science-based recommendations 
concerning the quality, safety and efficacy of medicinal products, especially 
when highly important to public health safeguard;
2. implementation of measures for continuous control of the quality, safety and 
 efficacy of legalized drugs, namely by guaranteeing a positive benefit/risk ratio;
3. publication of unbiased and reliable information on medicinal products; and
4. development of good practices for drug assessment and regulation in  
Europe, together with the promotion of harmonized international regulatory 
standards [21, 22].
The legal pharmacovigilance framework for human medicines marketed within 
the EU/European Economic Area (EEA) is given in Regulation (EC) No 726/2004, 
with regard to the EU authorized medicinal products, and Directive 2001/83/
EC, concerning the nationally authorized medicinal products, together with the 
Commission Implementing Regulation (EU) No 520/2012, which summarizes the 
practical aspects and obligations to be respected and followed by marketing autho-
rization holders and regulatory authorities. Posteriorly, the Directive 2010/84/EC 
was introduced to substitute the previous directive, with minor amendments being 
performed in 2012. The EU law requires marketing authorization holders, national 
competent authorities and EMA to operate services and processes in line with EU 
legislation, aiming to support a quality assured EU regulatory pharmacovigilance 
system and to reduce the number of ADR in EU [21–23]. The EU pharmacovigilance 
system is one of the most sophisticated and comprehensive in the world and allows 
monitoring the safety of medicines on the European market through prevention, 
detection and assessment of adverse reactions to drugs, leading to an increased 
level of public health protection throughout the EU. This system operates through 
a robust and close collaboration between the competent regulatory authorities 
from the EU member states, EMA (system coordinator responsible for centrally 
authorized drugs) and the European Commission (competent authority for drugs 
centrally authorized in the EU), to rapidly manage and act against an emerging 
problem, unceasingly prioritizing a safer and more efficacious access of patients to 
medicinal products. The Pharmacovigilance Risk Assessment Committee (PRAC) 
was formed in response to this need in July 2012, thus being responsible to provide 
recommendations on all aspects related to human drugs risk management [21–23].
The European pharmacovigilance network not only successfully collaborates 
at the European level with high transparency, but also coordinates the necessary 
regulatory actions, hence producing efficient and accurate safety results able to be 
transmitted to the EU public in a timely manner. Some of the regulatory tools acces-
sible after the implementation of the revised legislation involve risk management 
planning, signal detection and management at EU level, periodic safety update 
reports assessment, drug reviews through referrals post-authorization safety and 
efficacy studies, communication and training [23].
Within EU, the implementation of the different national pharmacovigilance sys-
tems occurred at distinct times. In 1963, The Netherlands became the first EU coun-
try to launch their own pharmacovigilance system for spontaneous ADR reporting, 
followed by the United Kingdom, in 1964, via the Yellow Card Scheme [24].
To achieve a consistent pharmacovigilance system, it is imperative that guide-
lines and standards are established as they clarify the practical details of the 
intended information flow, thus being very valuable, for instance, for health profes-
sionals training [5]. Thereby, the pharmacovigilance legislation in force in EU since 
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July 2012 led to the development of an important set of principles and measures 
on Good Pharmacovigilance Practices (GVP), to conduct the safety monitoring of 
medicines in EU [25]. One of the EMA’s advisors on the development of these guide-
lines and standards on operational features of the EU pharmacovigilance is PRAC 
[22]. The GVP guidelines, covering medicinal products authorized in the EU either 
centrally via EMA or nationally, apply to EU marketing authorization holders, EMA 
and the competent authorities from each member state. The GVP can slightly differ 
between countries, thus being established by each country regulatory authorities. 
Moreover, the guidelines set is divided into two chapter types [25]:
I. major Pharmacovigilance Processes (with each module referring only to one 
distinct process); and
II. Product- or Population-specific Considerations (includes vaccines, biological 
medicinal products and the pediatric population).
Although EMA is known to support several pharmacovigilance databases, 
the network system used for collecting, managing and analyzing suspected ADR 
related to authorized medicines within EEA is EudraVigilance. This electronic 
reporting database system allows the early detection of potential safety signals of 
post-marketed drugs by effectively analyzing the spontaneous reports previously 
submitted by marketing authorization holders and member states [26].
The Figure 1 below synthesizes the key features of pharmacovigilance for the 
global protection of the public health.
Appendices and nomenclature
ADR Adverse Drug Reaction
CIOMS Council for International Organizations of Medical Sciences
EEA European Economic Area
EMA European Medicines Agency
ESOP European Society of Pharmacovigilance
Figure 1. 
Pharmacovigilance (PV) highlights in public health safety.
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